A Randomized Controlled Trial to Assess Pharmacist-Physician Collaborative Practice in the Management of Metabolic Syndrome in a University Medical Clinic in Jordan

Hammad, Eman A.; Yasein, Nada; Tahaineh, Linda; Albsoul-Younes, Abla

doi:10.18553/jmcp.2011.17.4.295

Cited by 44 publications

(58 citation statements)

References 21 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The effectiveness of pharmacist-physician collaboration is consistent with previous published investigations of the role of pharmacists in the treatment of dyslipidemia, diabetes, hypertension (Ramser et al, 2008;Carter et al, 2009;Kelly, Booth, 2008;McLean et al, 2008) and metabolic syndrome (Hammad et al, 2011). Similarly, our results are also consistent with others studies performed in Brazil on the control of hypertension (Castro et al, 2006), diabetes (Correr et al, 2011) or hypertension and diabetes (Neto et al, 2011).…”

Section: Discussionsupporting

confidence: 93%

Reduction of cardiovascular risk in patients with metabolic syndrome in a community health center after a pharmaceutical care program of pharmacotherapy follow-up

Plaster

Melo

Boldt

et al. 2012

Braz. J. Pharm. Sci.

View full text Add to dashboard Cite

The objective of this study was to determine the impact of a pharmaceutical care (PC) program in a sample of public outpatients with metabolic syndrome (MS) who were being treated in Brazil's health system; the patients were randomized into PC or standard care. The pharmacotherapy follow-up (PF) was performed in a total of 120 patients with type 2 diabetes for 6 months. Adherence to treatment (measured with the Morisky test), negative outcomes associated with medication (NOM) and anthropometric and biochemical parameters were measured before and after PF. The Framingham scoring method was used to estimate changes in 10-year coronary heart disease risk scores in all patients. Ninety-six of 120 patients had characteristics of MS and were randomized into two groups (G): the control group (CG: 36) and the intervention group (IG: 38). Among the MS patients, 100% were taking a glucose-lowering drug; many were also taking anti-hypertensive drugs (CG: 72%; IG: 73%), and some patients were also taking hypolipemic drugs (CG: 12.0%; IG: 14.7%). Only 20.7% of the IG patients were considered adherent to their prescribed drugs. In the CG, an increase of coronary heart disease (CHD) risk (22±2 to 26±3; p<0.05) was observed, while in the IG, there was a reduction in CHD risk (22±2 to 14±2%; p<0.01). The PC program administered to patients with MS monitored through the primary healthcare services of the Brazilian public health system improved patient health, resulting in clinical improvements and a decrease in cardiovascular risk in IG patients over a period of ten years.
O objetivo deste estudo foi o de determinar o impacto de um Programa de atenção Farmacêutica (AF) em uma amostra de pacientes ambulatoriais de Sistema Público de Saúde do Brasil portadores de Síndrome Metabólica, randomizados em AF ou atenção à saúde usual. Realizou-se o seguimento farmacoterapêutico com 120 pacientes com diabetes tipo 2 durante seis meses. Avaliou-se o nível de aderência ao tratamento (teste Morisky), resultados clínicos negativos associados a medicamentos (RNM), parâmetros bioquímicos e antropométricos, antes e após o seguimento. O método de Framingham foi usado para calcular as variações no risco de doenças coronarianas em 10 anos em todos os pacientes. Dos 120 pacientes, 96 tiveram características de SM e foram então randomizados em dois grupos (G): Controle (GC: 36) e Intervenção (GI: 38). Entre os pacientes com SM, 100% faziam uso de medicamentos para diminuir a glicose, anti-hipertensivos (GC: 72%; GI: 73%) e hipoglicemiantes (GC: 12.0%; GI: 14.7%). Apenas 20,7% do GI foram considerados aderentes aos fármacos prescritos. No GC foi observado aumento do risco de Doença Arterial Coronariana (DAC) (22±2 para 26±3; p<0,05), enquanto no GI foi observado redução (22±2 para 14±2%; p<0,01). O Programa de AF para pacientes com SM monitorados na atenção primária do Sistema de Saúde Pública brasileiro melhora o funcionamento do serviço resultando na melhoria clínica dos pacientes com redução do risco de doença cardiovascular em um período de dez anos

show abstract

Section: Discussionsupporting

confidence: 93%

Reduction of cardiovascular risk in patients with metabolic syndrome in a community health center after a pharmaceutical care program of pharmacotherapy follow-up

Plaster

Melo

Boldt

et al. 2012

Braz. J. Pharm. Sci.

View full text Add to dashboard Cite

show abstract

“…Increase in disease-related knowledge can improve the medication adherence rates as seen in this study. Patients who were in direct contact with the pharmacist showed better preventive care attributes as required by the management guidelines [12]. The present study has demonstrated that increase in self-monitoring of blood glucose levels may improve glycemic control but this is not in agreement with the results of other studies [13].…”

Section: Discussioncontrasting

confidence: 88%

A Multifactorial Intervention to Enhance Adherence to Medications and Disease-Related Knowledge in Type 2 Diabetic Patients in Southern Punjab, Pakistan

Samtia¹,

Rasool²,

Ranjha³

et al. 2013

Trop. J. Pharm Res

View full text Add to dashboard Cite

)} compared to control group. The mean difference in glycemic control between both groups was insignificant but mild reductions were seen in fasting blood glucose p = 0.12). A significant increase in disease-related knowledge was seen in the intervention group, compared to the control group which was evident by mean differences in compliance (p = 0.003), foot-care (p < 0.001) and self-monitoring of blood glucose (p = 0.001

show abstract

“…The efficacy of the doctor-pharmacist collaboration studied is consistent with the findings of previous studies on the role of pharmacists in the treatment of DM2, HTN [19][20][21][22] and metabolic syndrome [23]. The results of this study are also consistent with others on the monitoring of HTN [24], DM2 [25] or HTN and DM2.…”

Section: Discussionsupporting

confidence: 91%

Drug Therapy Monitoring in Patients with Type 2 Diabetes and Hypertension

Bolívar¹,

Martínez-Mart́inez²,

Ferrit-Martin³

2017

JPP

View full text Add to dashboard Cite

Abstract:The aim of this paper is to detect, prevent and resolve DRP (drug-related problems) and NOM (negative outcomes associated with medication) in hospitalized patients with DM2 (type 2 diabetes) with HTN (hypertension) in a tertiary care clinic. Descriptive cross-sectional interventional study is used. DTM (drug therapy monitoring) was conducted in 73 patients using data obtained from clinical histories and interviews. NOM were detected based on symptoms and laboratory test results. The statistical significance was 0.05. It can be found that 23 DRP were detected, primarily in the category "likelihood of adverse effects" (30.43%) causing NOM in the "non-quantitative safety problem" category. The NOM detected were related to safety (62%), effectiveness (24.5%) and necessity (13.5%). Of the 68.57% of pharmacist interventions accepted, 48.57% were resolved and 20% were not resolved. A simple linear correlation (r = −0.34) analysis indicated a weak association between patient age and severity of NOM. DTM made it possible to detect suspected DRP and NOM, which were then prevented or resolved, improving the control of HTN and DM2 and helping ensure better drug therapy outcomes for patients.

show abstract

A Randomized Controlled Trial to Assess Pharmacist-Physician Collaborative Practice in the Management of Metabolic Syndrome in a University Medical Clinic in Jordan

Cited by 44 publications

References 21 publications

Reduction of cardiovascular risk in patients with metabolic syndrome in a community health center after a pharmaceutical care program of pharmacotherapy follow-up

Reduction of cardiovascular risk in patients with metabolic syndrome in a community health center after a pharmaceutical care program of pharmacotherapy follow-up

A Multifactorial Intervention to Enhance Adherence to Medications and Disease-Related Knowledge in Type 2 Diabetic Patients in Southern Punjab, Pakistan

Drug Therapy Monitoring in Patients with Type 2 Diabetes and Hypertension

Contact Info

Product

Resources

About